Objective: To compare the efficacy and adverse effects between arsenic trioxide (ATO) and all-trans retinoic acid (ATRA) in patients with acute promyelocytic leukemia (APL).
Methods: The clinical data of 71 patients with newly diagnosed APL were retrospectively analyzed. Two groups were classified according to the induction regimens, namely ATO group (n = 41) and ATRA group (n = 30). The complete remission (CR) rate and the time to CR were compared between these two groups.
Results: The CR rate was 97.5% in ATO group and 93.3% in ATRA group (P > 0.05). The median time to CR was 29 days (21-45 days) in ATO group, which was significantly shorter than 38.5 days (24-63 days) in ATRA group (P < 0.001). Retinoic acid syndrome occurred in 52.9% of patients treated with ATRA, which affected the further use of ATRA.
Conclusions: Both ATO and ATRA have high response rates for newly diagnosed patients with APL. Compared with ATRA, ATO induction therapy has shorter time to achieve CR and less adverse effects, and therefore may be the first-line therapy for APL.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Impact of Post-Traumatic Epilepsy on Mental Health and Multidimensional Outcome and Quality of Life: An NIDILRR TBIMS Study.
J Neurotrauma
January 2025
Department of Physical Medicine & Rehabilitation, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
Traumatic brain injury (TBI) and subsequent post-traumatic epilepsy (PTE) often impair daily activities and mental health (MH), which contribute to long-term TBI-related disability. PTE also affects driving capacity, which impacts functional independence, community participation, and satisfaction with life (SWL). However, studies evaluating the collective impact of PTE on multidimensional outcomes are lacking.
View Article and Find Full Text PDFBackground: Ruxolitinib cream has demonstrated anti-inflammatory and antipruritic activity and was well tolerated in a phase 3 study in patients aged 2-11 years with mild to moderate atopic dermatitis (AD).
Objective: This study examined the safety, tolerability, pharmacokinetics, efficacy, and quality of life (QoL) with ruxolitinib cream under maximum-use conditions and with longer-term use.
Methods: Eligible patients were aged 2-11 years with moderate to severe AD [Investigator's Global Assessment (IGA) score 3-4], and ≥ 35% affected body surface area (BSA).
Cytotoxicity and Oxidative Stress Induced by Technology-Critical Elements Traditional Metal Contaminants: An Bioassay Study.
Environ Sci Technol
January 2025
Department of Animal Biosciences, Swedish University of Agricultural Sciences, Box 7028, SE-750 07 Uppsala, Sweden.
Technology-critical elements (TCEs), essential in emerging technologies, are increasingly finding their way into our environment, raising concerns about their sparsely studied behavior and toxicity. To contribute insights into the toxicological aspects, we employed bioassays to investigate the possible cytotoxic effects in four representative cell lines (AR-EcoScreen GR-KO-M1, DR-EcoScreen, MCF7AREc32, VM7Luc4E2) and the potential to induce oxidative stress via the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway for a number of these elements. Nine TCEs, three rare-earth elements (REEs: Gd, Nd, Yb) and six less-studied TCEs (LSTCEs: Ga, Ge, In, Ta, Te, Tl), were selected for this study, along with three well-studied traditional metal contaminants (TMCs: As, Cd, Pb) for comparison.
View Article and Find Full Text PDFReal-world effectiveness and safety of bleomycin in patients with keloids and hypertrophic scars: a systematic review and meta-analysis.
Arch Dermatol Res
January 2025
Dermatology Department, Yanbian University Hospital, 1327 Juzi St, Yanji, 133002, Jilin, China.
Pathological scars are classified into hypertrophic scars and keloids, and currently have poor treatment outcomes and high recurrence rates. Bleomycin has received widespread attention in scar treatment in recent years, but there is currently no exploration on its real-world data. PubMed, Embase, and Cochrane databases were searched, and eight retrospective studies on the use of bleomycin for treatment were included, covering a total of 562 patients with keloids and hypertrophic scars.
View Article and Find Full Text PDFRisk and Protective Factors of Poor Clinical Outcomes in Heart Failure with Improved Ejection Fraction Population: A Systematic Review and Meta-Analysis.
Curr Cardiol Rep
January 2025
Faculty of Medicine, University of Padjadjaran, Bandung, Indonesia.
Aims: Heart failure with improved ejection fraction (HFimpEF) patients could still develop adverse outcomes despite EF improvement. This study evaluates the risk and protective factors of poor clinical outcomes in HFimpEF patients.
Methods: Systematic searching was done to include studies that evaluate the risks of developing poor outcomes in HFimpEF patients.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!